摘要
动脉粥样硬化(AS)是冠状动脉粥样硬化性心脏病(冠心病)的病理基础。冠心病强化药物治疗后仍有较高的心血管残存风险。随着CANTOS试验的发表,基于炎症理论干预冠心病取得突破性进展,炎症可能成为冠心病新的治疗靶点。近年来,中医药在抗炎干预冠心病方面进行了积极的探索。本文总结了相关中医药研究,旨在为从"干预炎症反应"角度发挥中西医优势互补效应治疗冠心病展示新的视角。
Atherosclerosis(AS)is the pathological basis of coronary atherosclerotic heart disease(CHD).Even with intensive drug therapy,the risk of cardiovascular residual is still high.With the publication of CANTOS trial,breakthroughs have been made in the intervention of CHD based on inflammation theory.Inflammation may become a new therapeutic target for CHD.In recent years,Chinese medicine has actively explored anti-inflammatory intervention in CHD treatment.This paper summarizes the relevant research of Chinese medicine,aiming at displaying a new perspective for the treatment of CHD from'intervention of inflammation response'and giving full play to the complementary effect of advantages of traditional Chinese and Western medicine.
作者
李思铭
李金根
徐浩
LI Si-ming;LI Jin-gen;XU Hao(Cardiovascular Disease Center,Xiyuan Hospital of China Academy of Chinese Medical Sciences,Beijing 100091;Graduate School of Beijing University of Chinese Medicine,Beijing 100029)
出处
《中国中西医结合杂志》
CAS
CSCD
北大核心
2019年第4期486-490,共5页
Chinese Journal of Integrated Traditional and Western Medicine
基金
北京市科技计划首都临床特色应用研究与成果推广项目(No.Z151100004015090)
关键词
动脉粥样硬化
冠心病
炎症
中医药
atherosclerosis
coronary heart disease
inflammation
Chinese medicine
